ONCR - Oncorus, Inc.
Pre-Market:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.1060 |
| Open | 0.1158 |
| Bid | 0.1043 x 1800 |
| Ask | 0.1050 x 1000 |
| Day's Range | 0.1030 - 0.1169 |
| 52 Week Range | 0.0920 - 1.7800 |
| Volume | |
| Avg. Volume | 838,977 |
| Market Cap | 2.852M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.3200 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Related Research
ZacksOncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
GlobeNewswireOncorus Announces Workforce Reduction Plan
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55
- GlobeNewswire
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneeri
- GlobeNewswire
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administrationEnded the quarter with $62.2 million in cash, cash equivalents and investments to support next-generation RNA therapeutics pipeline ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines compan
- GlobeNewswire
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and D
American City Business JournalsCancer biotech cuts staff by one-fifth
Boston biotech Oncorus Inc. is losing one-fifth of its employees as it pauses work on all but one drug. Oncorus (Nasdaq: ONCR) announced the cuts on Wednesday, saying it will lay off 20% of its staff. ONCR-021 is still preclinical, but Oncorus believes it could have applications in non-small cell lung cancer, hepatocellular carcinoma, clear cell renal cell carcinoma and melanoma.
BenzingaOncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce
Oncorus Inc (NASDAQ: ONCR) is reprioritizing its pipeline and is discontinuing the Phase 1 trial of ONCR-177 to focus resources on ONCR-021. In addition, the company is discontinuing the development of ONCR-177, reducing its workforce and burn rate, and reiterating guidance for its cash runway into early 2024. Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023. Related: Chardan Sees Over 200% Upsid
- GlobeNewswire
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company’s cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, In
- GlobeNewswire
Oncorus to Participate in Upcoming Investor Conferences
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences: Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.Piper Sandler 34th Annual Healthcare Conference
- GlobeNewswire
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 expresses four immunomodulatory payloads, including IL-12, an anti-PD-1 nanobody, 15-hydroxyprostaglandin dehydrogenase (HPGD), and a novel macrophage-modulating Fc-enhanced antibody to reverse GBM’s immunosu
ZacksOncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to submit IND for ONCR-021 in mid-2023Completed construction phase of GMP-compliant manufacturing facility in Andover, MAEnded the quarter with $81.5 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies comp
- GlobeNewswire
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA (vRNA)/lipid nanoparticle (LNP) platform as a nov
- GlobeNewswire
Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be accessed by visiting the
- GlobeNewswire
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:00 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed
Simply Wall St.Oncorus, Inc. (NASDAQ:ONCR) insiders recover some losses but still US$100k away from matching original investment
Insiders who purchased US$231k worth of Oncorus, Inc. ( NASDAQ:ONCR ) shares over the past year recouped some of their...
- GlobeNewswire
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track to submit IND for ONCR-021 in mid-2023Ended quarter with $100.2 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients,
ZacksHere's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for Oncorus, Inc. (ONCR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Simply Wall St.
An Intrinsic Calculation For Oncorus, Inc. (NASDAQ:ONCR) Suggests It's 44% Undervalued
Today we will run through one way of estimating the intrinsic value of Oncorus, Inc. ( NASDAQ:ONCR ) by estimating the...
- GlobeNewswire
Oncorus Appoints Douglas Fambrough to Board of Directors
-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. “We are thrilled to welcome Doug to our board and leverage his significant expertise and executive lea
BenzingaChardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock
Chardan has initiated coverage on Oncorus Inc (NASDAQ: ONCR) with a Buy rating and a price target of $5. The analysts based it on the company's commercial potential with its lead oncolytic virus immunotherapy ONCR-177 from its HSV platform. Oncorus' HSV platform utilizes the herpes simplex virus (HSV) type 1 backbone that incorporates more transgenes, retains the ability to replicate in tumor cells, and has orthogonal safety strategies to attenuate viral replication in healthy tissues. Related: